Cargando…
Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1–May 6, 2018
Lassa fever (LF) is endemic to Nigeria, where the disease causes substantial rates of illness and death. In this article, we report an analysis of the epidemiologic and clinical aspects of the LF outbreak that occurred in Nigeria during January 1–May 6, 2018. A total of 1,893 cases were reported; 42...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537738/ https://www.ncbi.nlm.nih.gov/pubmed/31107222 http://dx.doi.org/10.3201/eid2506.181035 |
_version_ | 1783422080780337152 |
---|---|
author | Ilori, Elsie A. Furuse, Yuki Ipadeola, Oladipupo B. Dan-Nwafor, Chioma C. Abubakar, Anwar Womi-Eteng, Oboma E. Ogbaini-Emovon, Ephraim Okogbenin, Sylvanus Unigwe, Uche Ogah, Emeka Ayodeji, Olufemi Abejegah, Chukwuyem Liasu, Ahmed A. Musa, Emmanuel O. Woldetsadik, Solomon F. Lasuba, Clement L.P. Alemu, Wondimagegnehu Ihekweazu, Chikwe |
author_facet | Ilori, Elsie A. Furuse, Yuki Ipadeola, Oladipupo B. Dan-Nwafor, Chioma C. Abubakar, Anwar Womi-Eteng, Oboma E. Ogbaini-Emovon, Ephraim Okogbenin, Sylvanus Unigwe, Uche Ogah, Emeka Ayodeji, Olufemi Abejegah, Chukwuyem Liasu, Ahmed A. Musa, Emmanuel O. Woldetsadik, Solomon F. Lasuba, Clement L.P. Alemu, Wondimagegnehu Ihekweazu, Chikwe |
author_sort | Ilori, Elsie A. |
collection | PubMed |
description | Lassa fever (LF) is endemic to Nigeria, where the disease causes substantial rates of illness and death. In this article, we report an analysis of the epidemiologic and clinical aspects of the LF outbreak that occurred in Nigeria during January 1–May 6, 2018. A total of 1,893 cases were reported; 423 were laboratory-confirmed cases, among which 106 deaths were recorded (case-fatality rate 25.1%). Among all confirmed cases, 37 occurred in healthcare workers. The secondary attack rate among 5,001 contacts was 0.56%. Most (80.6%) confirmed cases were reported from 3 states (Edo, Ondo, and Ebonyi). Fatal outcomes were significantly associated with being elderly; no administration of ribavirin; and the presence of a cough, hemorrhaging, and unconsciousness. The findings in this study should lead to further LF research and provide guidance to those preparing to respond to future outbreaks. |
format | Online Article Text |
id | pubmed-6537738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-65377382019-06-05 Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1–May 6, 2018 Ilori, Elsie A. Furuse, Yuki Ipadeola, Oladipupo B. Dan-Nwafor, Chioma C. Abubakar, Anwar Womi-Eteng, Oboma E. Ogbaini-Emovon, Ephraim Okogbenin, Sylvanus Unigwe, Uche Ogah, Emeka Ayodeji, Olufemi Abejegah, Chukwuyem Liasu, Ahmed A. Musa, Emmanuel O. Woldetsadik, Solomon F. Lasuba, Clement L.P. Alemu, Wondimagegnehu Ihekweazu, Chikwe Emerg Infect Dis Synopsis Lassa fever (LF) is endemic to Nigeria, where the disease causes substantial rates of illness and death. In this article, we report an analysis of the epidemiologic and clinical aspects of the LF outbreak that occurred in Nigeria during January 1–May 6, 2018. A total of 1,893 cases were reported; 423 were laboratory-confirmed cases, among which 106 deaths were recorded (case-fatality rate 25.1%). Among all confirmed cases, 37 occurred in healthcare workers. The secondary attack rate among 5,001 contacts was 0.56%. Most (80.6%) confirmed cases were reported from 3 states (Edo, Ondo, and Ebonyi). Fatal outcomes were significantly associated with being elderly; no administration of ribavirin; and the presence of a cough, hemorrhaging, and unconsciousness. The findings in this study should lead to further LF research and provide guidance to those preparing to respond to future outbreaks. Centers for Disease Control and Prevention 2019-06 /pmc/articles/PMC6537738/ /pubmed/31107222 http://dx.doi.org/10.3201/eid2506.181035 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Synopsis Ilori, Elsie A. Furuse, Yuki Ipadeola, Oladipupo B. Dan-Nwafor, Chioma C. Abubakar, Anwar Womi-Eteng, Oboma E. Ogbaini-Emovon, Ephraim Okogbenin, Sylvanus Unigwe, Uche Ogah, Emeka Ayodeji, Olufemi Abejegah, Chukwuyem Liasu, Ahmed A. Musa, Emmanuel O. Woldetsadik, Solomon F. Lasuba, Clement L.P. Alemu, Wondimagegnehu Ihekweazu, Chikwe Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1–May 6, 2018 |
title | Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1–May 6, 2018 |
title_full | Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1–May 6, 2018 |
title_fullStr | Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1–May 6, 2018 |
title_full_unstemmed | Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1–May 6, 2018 |
title_short | Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1–May 6, 2018 |
title_sort | epidemiologic and clinical features of lassa fever outbreak in nigeria, january 1–may 6, 2018 |
topic | Synopsis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537738/ https://www.ncbi.nlm.nih.gov/pubmed/31107222 http://dx.doi.org/10.3201/eid2506.181035 |
work_keys_str_mv | AT ilorielsiea epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT furuseyuki epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT ipadeolaoladipupob epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT dannwaforchiomac epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT abubakaranwar epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT womietengobomae epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT ogbainiemovonephraim epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT okogbeninsylvanus epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT unigweuche epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT ogahemeka epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT ayodejiolufemi epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT abejegahchukwuyem epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT liasuahmeda epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT musaemmanuelo epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT woldetsadiksolomonf epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT lasubaclementlp epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT alemuwondimagegnehu epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT ihekweazuchikwe epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 AT epidemiologicandclinicalfeaturesoflassafeveroutbreakinnigeriajanuary1may62018 |